Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $72.13, for a total transaction of $577,040.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
TRHC traded down $1.12 during midday trading on Thursday, hitting $73.81. 205,600 shares of the company’s stock traded hands, compared to its average volume of 347,196. The firm has a market cap of $1.36 billion, a PE ratio of -1,845.25, a PEG ratio of 5.08 and a beta of 2.58. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.33 and a current ratio of 0.36. Tabula Rasa HealthCare Inc has a one year low of $27.10 and a one year high of $91.16.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.07. The firm had revenue of $54.42 million for the quarter, compared to analyst estimates of $52.87 million. Tabula Rasa HealthCare had a negative net margin of 13.49% and a positive return on equity of 7.53%. The company’s revenue for the quarter was up 66.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 earnings per share. On average, sell-side analysts anticipate that Tabula Rasa HealthCare Inc will post 0.53 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. Comerica Bank bought a new position in Tabula Rasa HealthCare during the second quarter valued at approximately $947,000. Citadel Advisors LLC raised its position in Tabula Rasa HealthCare by 47.0% during the second quarter. Citadel Advisors LLC now owns 8,855 shares of the company’s stock valued at $565,000 after acquiring an additional 2,832 shares in the last quarter. Pitcairn Co. bought a new position in Tabula Rasa HealthCare during the second quarter valued at approximately $285,000. Rhumbline Advisers raised its position in Tabula Rasa HealthCare by 34.5% during the second quarter. Rhumbline Advisers now owns 36,119 shares of the company’s stock valued at $2,305,000 after acquiring an additional 9,272 shares in the last quarter. Finally, BlackRock Inc. raised its position in Tabula Rasa HealthCare by 29.7% during the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock valued at $135,288,000 after acquiring an additional 484,979 shares in the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Recommended Story: How does inflation affect different investments?
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.